好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Tau PET Imaging in Black and Latino Individuals
Aging, Dementia, and Behavioral Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
12-010
Determine whether tau-PET findings generalize to Black and Latino participants who continue to be underrepresented in dementia research.
Tau-PET neuroimaging is increasingly used to diagnose, stage, and assess response to disease-modifying treatments in individuals with Alzheimer disease, yet studies evaluating tau PET applications have predominantly been completed in non-Hispanic White (nHW) participants. 
Community-dwelling Black and Latino participants completed MRI, and amyloid- (PiB or florbetapir) and tau- (flortaucipir) PET brain imaging as part of a longitudinal study of memory and aging. Global and regional tau-PET standardized uptake value ratios (normalized to the cerebellar crus) were determined in Black and Latino participants and compared with findings in nHW participants, 1:1-matched for age, sex, education, and global Clinical Dementia Rating®. Conditional logistic modeling compared 47 regions of interest, adjusted for false discovery rate. Relevant associations between flortaucipir retention and clinical outcomes were assessed using Spearman rank correlations. 
105 Black (mean 71.3±11.0 years-old, 65% female, 34% cognitively impaired), 37 Latino (mean 65.2±8.2 -years-old, 51% female, 22% cognitively impaired) and 142 matched nHW participants completed neuroimaging. Tau-PET burden was similar between matched cohorts (Black and nHW participants, mean SUVR: 1.37±0.41 vs 1.32±0.36, p=0.20; Latino and nHW participants, mean SUVR: 1.30±0.41 vs 1.27±0.29, p=0.69). Lower flortaucipir uptake was noted in the caudate (p=0.02), putamen (p=0.03), and pallidum (p=0.02) of Black vs nHW participants. Global flortaucipir retention increased with age (Black: Rho=0.223; nHW: Rho=0.243; p<0.05), amyloid Centiloids (Black: Rho=0.649; Latino: Rho=0.474; nHW: Rho=0.693; p<0.01), and cognitive impairment (i.e., Clinical Dementia Rating® Sum-of-Box scores, Black: Rho=0.53; Latino: Rho=0.489; nHW: Rho=0.533; p<0.01).

Tau-PET patterns were similar across ethnoracial groups, with flortaucipir retention increasing with age, amyloid accumulation, and the severity of cognitive impairment. These findings affirm the clinical and research applications of tau PET in diverse cohorts.
Authors/Disclosures
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic)
PRESENTER 		Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has or had stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Amgen Pharmaceuticals. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with 好色先生. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing 好色先生, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Ionis Pharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Case Development + Presentation (video) with PeerDirect (P\S\L Group). Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development / Presentation (non-CME) with MJH Life Sciences (NeurologyLive). Dr. Day has a non-compensated relationship as a Clinical Director with Anti-NMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.
Scott Przybelski Scott Przybelski has nothing to disclose.
Manoj K. Jain, MD, MBBS Dr. Jain has nothing to disclose.
Christian Lachner Christian Lachner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PeerView. Christian Lachner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PSL Group Services.
Yoav Piura, MD Dr. Piura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Piura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck.
Paula A. Aduen, PhD Dr. Aduen has nothing to disclose.
Leah Schecter, MD Dr. Schecter has nothing to disclose.
Angela Fought (Mayo Clinic) Angela Fought has received personal compensation in the range of $500-$4,999 for serving as a Biostatistician on DSMB with Northwestern University.
Patricia Diaz-Galvan, PhD Dr. Diaz-Galvan has nothing to disclose.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Christopher Schwarz The institution of Christopher Schwarz has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. The institution of Dr. Kantarci has received research support from Eisai. The institution of Dr. Kantarci has received research support from BioArctic.
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville) The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.